Biocept Inc (BIOC) is trading up 20.22% at $1.07 per share so far Thursday. Biocept is up sharp after announcing a development agreement with Aegea for the creation of a highly sensitive PCR assay for the detection of COVID-19.
Biocept Inc (BIOC) stock is higher by 5.94% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives BIOC stock a score of 80 out of a possible 100.
That score is chiefly influenced by a long-term technical score of 93. BIOC’s score also includes a fundamental score of 81. In addition to the average rating from Wall Street analysts, BIOC stock has a mean target price of 1.53. This means analysts expect the stock to rise 42.99% over the next 12 months. The short-term technical score for BIOC is 65.
What’s Happening with BIOC Stock Today
Biocept Inc (BIOC) stock is trading at $1.07 as of 11:38 AM on Thursday, Aug 6, a rise of $0.18, or 20.09% from the previous closing price of $0.89. The stock has traded between $1.06 and $1.30 so far today. Volume today is more active than usual. So far 118,202,161 shares have traded compared to average volume of 19,377,557 shares.
